NASDAQ:JNCE - Jounce Therapeutics Stock Price, Forecast & News

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics Inc (NASDAQ:JNCE) released its earnings results on Thursday, November, 7th. The company reported $2.90 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.24 by $0.66. The firm earned $119.45 million during the quarter, compared to analysts' expectations of $99.97 million. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 64.54%. View Jounce Therapeutics' Earnings History.

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Jounce Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

News headlines about JNCE stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jounce Therapeutics earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Jounce Therapeutics.

Jounce Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 425,400 shares, an increase of 40.9% from the September 15th total of 302,000 shares. Based on an average trading volume of 125,200 shares, the short-interest ratio is presently 3.4 days. Currently, 2.8% of the company's shares are short sold. View Jounce Therapeutics' Current Options Chain.

Some companies that are related to Jounce Therapeutics include Fate Therapeutics (FATE), Precision BioSciences (DTIL), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Rubius Therapeutics (RUBY), BAVARIAN NORDIC/S (BVNRY), Vericel (VCEL), Twist Bioscience (TWST), MeiraGTx (MGTX), Cortexyme (CRTX), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM), DBV TECHNOLOGIE/S (DBVT), Osiris Therapeutics (OSIR) and AVITA MED LTD/S (AVMXY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Progenics Pharmaceuticals (PGNX), Teva Pharmaceutical Industries (TEVA), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD), Clovis Oncology (CLVS) and Sorrento Therapeutics (SRNE).

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.27%), Millennium Management LLC (0.48%), Strs Ohio (0.47%), Granahan Investment Management Inc. MA (0.37%), Essex Investment Management Co. LLC (0.33%) and Russell Investments Group Ltd. (0.10%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole and Kimberlee C Drapkin. View Insider Buying and Selling for Jounce Therapeutics.

JNCE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Essex Investment Management Co. LLC, Strs Ohio, State Street Corp, Russell Investments Group Ltd., Meeder Asset Management Inc., Tower Research Capital LLC TRC and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $8.17.

Jounce Therapeutics has a market capitalization of $271.49 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.